NewLink Genetics (NLNK): Investor Day Focus on IDO Combos - Jefferies

October 26, 2016 8:28 AM EDT
Get Alerts NLNK Hot Sheet
Price: $12.02 --0%

Rating Summary:
    5 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade NLNK Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies analyst, Biren Amin, reiterated his Hold rating on shares of NewLink Genetics (NASDAQ: NLNK) and raised the price target to $12 from $10 after the company hosted an analyst day focused on opportunities for IDO in combo in multiple tumor types.

Management reiterated that its strategy includes multiple shots on goal with indoximod and GDC-0919 (partnered). Plans are being made to move indoximod into late stage trials in 2H17 based on multiple readouts from ongoing PII trials.

A PII single arm Indoximod trial in melanoma combo with ipi, pembro, and nivo has enrolled 75% of 96 expected pts with data in 2H17.

For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.

Shares of NewLink Genetics closed at $13.63 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment